CNBC

CNBC   |  January 01, 1910

Cancer innovations

ImClone Systems’ drug Erbitux, which has shown a survival benefit for head and neck cancer patients, stole the show at this year’s annual meeting of the American Society of Clinical Oncology (ASCO), which takes place in New Orleans this week, CNBC's Mike Huckman reports.

Share This:

Sorry, we do not have a transcript available for this video at this time.